These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 2879296)

  • 21. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
    Soyka M; Winter C; Kagerer S; Brunnauer M; Laux G; Möller HJ
    J Psychiatr Res; 2005 Jan; 39(1):101-8. PubMed ID: 15504428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction and evaluation criteria in perazine therapy of acute schizophrenics: psychopathological results.
    Schied HW; Rein W; Straube E; Jung H; Breyer-Pfaff U
    Pharmacopsychiatria; 1983 Sep; 16(5):152-9. PubMed ID: 6140694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
    Delcker A; Schoon ML; Oczkowski B; Gaertner HJ
    Pharmacopsychiatry; 1990 May; 23(3):125-30. PubMed ID: 1973843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No correlation between neuroleptic-induced increase of beta-endorphin serum level and therapeutic efficacy in schizophrenia.
    Naber D; Nedopil N; Eben E
    Br J Psychiatry; 1984 Jun; 144():651-3. PubMed ID: 6146374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia.
    Kowalski J; Blada P; Kucia K; Madej A; Herman ZS
    Schizophr Res; 2001 Jul; 50(3):169-75. PubMed ID: 11439237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.
    Pietzcker A; Poppenberg A; Schley J; Müller-Oerlinghausen B
    Arch Psychiatr Nervenkr (1970); 1981; 229(4):315-29. PubMed ID: 6111989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia.
    Gaebel W; Müller-Oerlinghausen B; Schley J
    Prog Neuropsychopharmacol Biol Psychiatry; 1992; 16(6):891-900. PubMed ID: 1355303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orthostatic challenge during neuroleptic test dose: a possible predictor of short-term outcome.
    Volz HP; Mackert A; Diefenbacher A; Friedrich A; Gaebel W; Müller H; Stock G; Möller HJ
    Neuropsychobiology; 1994; 30(2-3):94-100. PubMed ID: 7800170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Perazine therapy. Seminar, Hamburg, 12-14 November 1992].
    Nervenarzt; 1993 Jan; 64(1 Suppl):1-8. PubMed ID: 7477594
    [No Abstract]   [Full Text] [Related]  

  • 34. Binding of perazine to alpha 1-acid glycoprotein.
    Schley J; Siegert M; Müller-Oerlinghausen B
    Eur J Clin Pharmacol; 1980 Nov; 18(6):501-4. PubMed ID: 6109633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of neuroleptic on-drug response in schizophrenic in-patients by EEG.
    Ulrich G; Gaebel W; Pietzcker A; Müller-Oerlinghausen B; Stieglitz RD
    Eur Arch Psychiatry Neurol Sci; 1988; 237(3):144-55. PubMed ID: 2898366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perazine for schizophrenia.
    Leucht S; Helfer B; Hartung B
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD002832. PubMed ID: 24425538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment? Results of a preliminary study.
    Meya U; Renfordt E
    Pharmacopsychiatry; 1986 Nov; 19(6):429-33. PubMed ID: 2879296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
    Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
    Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
    [No Abstract]   [Full Text] [Related]  

  • 39. Initial improvement as a criterion for drug choice in acute schizophrenia.
    Klimke A; Klieser E; Lehmann E; Miele L
    Pharmacopsychiatry; 1993 Jan; 26(1):25-9. PubMed ID: 8104348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A differential effect profile of neuroleptic therapy of acute schizophrenic patients? Results of a clinico-naturalistic study].
    Schmidt LG; Siemetzki H
    Nervenarzt; 1988 Dec; 59(12):721-6. PubMed ID: 2905770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.